Contributions
Abstract: PB1748
Type: Publication Only
Background
Acute myeloid leukemia (AML) is widely considered as a distinct clinical entity with a well-defined molecular and genetics-based prognosis. Particularly, in the younger patient the therapeutic approach depends largely on diagnostic risk stratification, which has an impact on the outcome after therapy.
Aims
We have added T regs evaluation to the usual molecular and cytogenetics profile in the AML younger patients diagnostic bone marrow aspirate (dBMA) in order to look for any correlation between Tregs and overall response (OR) as well as survival (OS) rates.
Methods
The study included 19 AML patients (12 males and 7 females, median age 57 years, range 20-65) all treated with “3+7” regimen. According to cytogenetic-molecular risk stratification: 2 (11%), 9 (47%) and 8 (42%) patients were assigned to the favorable, intermediate and adverse prognosis groups, respectively. Molecular evaluation (i.e. NPM; FLT3; CEBPA) was performed in all cases: NPM1 (A or B mutation) and FLT3 mutations (ITD or D835) were positive in 3 (16%) and 3 (16%) patients, respectively. There were no CEBPA positive cases. Median values of white blood cells (WBC) were 10400/uL and of dBMA Tregs 21/uL.
Results
OR (Complete remission (CR) + CR incomplete (CRi)) was documented in 7 of 19 patients (37%); there were two partial responderpatients. The optimal dBMA-Tregs cut-off value for predicting response to treatment (>21/uL) was obtained by ROC curve analysis. Apart from the expected impact of the molecular/cytogenetic group (p=0.05) and the NPM mutation (p=0.036), OR was also correlated with dBMA Tregs >21/uL (p=0.020). Furthermore, the same Tregs value seemed to correlate with a better median OS (21 vs 4 months, Log-Rank test, p=0.028).
Conclusion
Obviously, the possible prognostic value in terms of OR and survival rates of such an immunological player as BMA Tregs should be confirmed in larger patients numbers
Session topic: 4. Acute myeloid leukemia - Clinical
Keyword(s): Acute Myeloid Leukemia, prognosis, T regulatory cells
Abstract: PB1748
Type: Publication Only
Background
Acute myeloid leukemia (AML) is widely considered as a distinct clinical entity with a well-defined molecular and genetics-based prognosis. Particularly, in the younger patient the therapeutic approach depends largely on diagnostic risk stratification, which has an impact on the outcome after therapy.
Aims
We have added T regs evaluation to the usual molecular and cytogenetics profile in the AML younger patients diagnostic bone marrow aspirate (dBMA) in order to look for any correlation between Tregs and overall response (OR) as well as survival (OS) rates.
Methods
The study included 19 AML patients (12 males and 7 females, median age 57 years, range 20-65) all treated with “3+7” regimen. According to cytogenetic-molecular risk stratification: 2 (11%), 9 (47%) and 8 (42%) patients were assigned to the favorable, intermediate and adverse prognosis groups, respectively. Molecular evaluation (i.e. NPM; FLT3; CEBPA) was performed in all cases: NPM1 (A or B mutation) and FLT3 mutations (ITD or D835) were positive in 3 (16%) and 3 (16%) patients, respectively. There were no CEBPA positive cases. Median values of white blood cells (WBC) were 10400/uL and of dBMA Tregs 21/uL.
Results
OR (Complete remission (CR) + CR incomplete (CRi)) was documented in 7 of 19 patients (37%); there were two partial responderpatients. The optimal dBMA-Tregs cut-off value for predicting response to treatment (>21/uL) was obtained by ROC curve analysis. Apart from the expected impact of the molecular/cytogenetic group (p=0.05) and the NPM mutation (p=0.036), OR was also correlated with dBMA Tregs >21/uL (p=0.020). Furthermore, the same Tregs value seemed to correlate with a better median OS (21 vs 4 months, Log-Rank test, p=0.028).
Conclusion
Obviously, the possible prognostic value in terms of OR and survival rates of such an immunological player as BMA Tregs should be confirmed in larger patients numbers
Session topic: 4. Acute myeloid leukemia - Clinical
Keyword(s): Acute Myeloid Leukemia, prognosis, T regulatory cells